AbbVie, C2N Diagnostics Partner for Alzheimer’s Drug Development
AbbVie has entered into an exclusive worldwide license agreement with C2N Diagnostics, a privately held protein diagnostic and therapeutic discovery company, to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer’s disease and other neurological disorders. Financial terms of the collaboration were not disclosed.
Tau stabilizes proteins that are responsible for the structure and transport in neuronal cells. Abnormal accumulation of altered tau protein is a leading indicator in a variety of neurodegenerative conditions, including Alzheimer’s disease, progressive supranuclear palsy, and corticobasal degeneration. In these conditions, the development of tau pathology strongly correlates with clinical disease progression.
C2N Diagnostics, LLC was formed by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, Missouri and LifeTech Research, a Maryland-based technology research and venture development firm. C2N is commercializing a suite of biomarker assays and tools to enable drug discovery, clinical drug development, and early detection of neurodegenerative disorders.